Personalized treatment for IgA kidney disease
Part of Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests whether choosing treatment based on your personal kidney findings can improve outcomes in adults with IgA nephropathy (IgAN). It may help by matching therapy to the type and severity of kidney damage seen on biopsy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 to 70
- Your IgA nephropathy diagnosis was confirmed by a kidney biopsy
- Your biopsy shows active, chronic, or moderate kidney lesions
- You do not have nephrotic syndrome caused by minimal change disease on biopsy
- You have not taken immune-suppressing medicines before (or at least none in a way that disqualifies you)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational medication for two rare kidney conditions that cause inflammation and protein in the urine. It aims to see if the drug is safe and helps control the disease, potentially slowing kidney damage.
This trial tests a personalized approach that uses a blood test to help guide targeted therapies for IgA nephropathy and IgA vasculitis. It may help reduce kidney damage and control the disease with fewer side effects.
This trial tests whether immunosuppressive therapy (medicine that calms the immune system) helps people with IgA nephropathy and moderately to severely reduced kidney function. It is intended for adults with confirmed IgA kidney disease who still have significant protein in the urine despite standard blood-pressure kidney protection treatment.
This trial enrolls teens and adults with biopsy-proven IgA nephropathy to help doctors learn whether a specific care approach works better for high-quality treatment. It is meant for people whose IgA kidney disease is the primary form (not caused by another illness).
This trial tests a new gene therapy called PS-002 for adults with IgA nephropathy, a kidney disease that can lead to kidney failure. The treatment aims to reduce kidney damage, and this study will help determine if it is safe and effective.
This trial tests an experimental tablet, HSK39297, for people with IgA nephropathy, a kidney disease. It aims to see if the drug is safe and can help reduce protein in the urine, which is a sign of kidney damage.
Hear when a new Glomerulonephritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.